Abstract
Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.
| Original language | English |
|---|---|
| Pages (from-to) | 535-544 |
| Number of pages | 10 |
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 14 |
| Issue number | 5 |
| Early online date | 21 Mar 2021 |
| DOIs | |
| Publication status | Published - 31 Dec 2021 |
Keywords
- Darolutamide
- androgen receptor antagonist
- castration-resistant
- hormone-sensitive
- non-metastatic
- prostate cancer
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)
Access to Document
- Drug_profile_Darolutamide_ADA (2)
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert review of clinical pharmacology on 21/3/2021, available online: https://www.tandfonline.com/doi/abs/10.1080/17512433.2021.1901580?journalCode=ierj20